Sector Expert: Jim Birchenough

Wells Fargo Securities

With more than two decades of experience as a physician, pharmaceutical industry veteran and sell side analyst, Dr. Jim Birchenough has covered a broad range of small-, mid- and large-cap biotech companies. He has an emphasis on clinical discovery and emerging technologies and companies and is highly rated in various investor surveys. He holds a Post-Graduate Medical Residency and a Medical Doctorate from McMaster University and a Bachelor of Science in physiology from McGill University.

Subscribe to
Streetwise Reports

Companies Commented On

  • Sunesis Pharmaceuticals Inc.


Recent Quotes

"We are maintaining our Outperform rating on SNSS; we see significant upside potential on novel BTK inhibitor SNS062."

— Jim Birchenough, Wells Fargo Securities (5/1/17)
more >

"SNSS has a potential blockbuster opportunity with SNS062."

— Jim Birchenough, Wells Fargo Securities (1/31/17)
more >



Due to permission requirements, not all quotes are shown.